---
search:
  boost: 3
---

# Urinary Antispasmodics

This is a subcategory of Genitourinary Agents.

## Decision Tree

- [Genitourinary - Urinary Antispasmodics - Myrbetriq Granules](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMlpWNjdMNVM3OFRBSFFFMkNCVDZBNjRCSiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Genitourinary - Urinary Antispasmodics- Non-Preferred - Darifenacin, Fesoterodine*, Gemtesa, Tolterodine, Trospium](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNjhDODBCSzJZSDVDMTlXQjQ5TkNVVVBWNCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Genitourinary - Urinary Antispasmodics- Non-Preferred (Age Restricted) - Vesicare LS](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURTJOV0lUR1UyMFlDNjNYOTZRNU4ySU1EQyQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                  | Generic Name                                         | Quantity | Time (Days) |
|:-------------------------------------------|:-----------------------------------------------------|:--------:|:-----------:|
| Gelnique                                   |                                                      |          |             |
| Myrbetriq Tab                              |                                                      |          |             |
| Oxybutynin <sup>QL</sup>                   | Oxybutynin Chloride Tab 5 MG                         |   408    |     102     |
| Oxybutynin ER <sup>QL</sup>                | Oxybutynin Chloride ER Tab (all strengths excl 5 MG) |   204    |     102     |
| Oxybutynin ER <sup>QL</sup>                | Oxybutynin Chloride ER Tab 5 MG                      |   102    |     102     |
| Oxytrol                                    |                                                      |          |             |
| Solifenacin <sup>QL</sup>                  | Solifenacin Succinate Tab (all strengths)            |   102    |     102     |
| Toviaz <sup>BvG ==(Process by NDC)==</sup> |                                                      |          |             |

### Non-Preferred

| Non-Preferred                                                                          | Generic Name                                    |         Quantity          |        Time (Days)        |
|:---------------------------------------------------------------------------------------|:------------------------------------------------|:-------------------------:|:-------------------------:|
| Darifenacin <sup>QL</sup>                                                              | Darifenacin Hydrobromide ER Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| <span title = "Brand Preferred: Toviaz">Fesoterodine</span> <sup>Brand Preferred</sup> |                                                 |                           |                           |
| Gemtesa                                                                                |                                                 |                           |                           |
| Myrbetriq Granules <sup>AR</sup>                                                       |                                                 |                           |                           |
| Tolterodine                                                                            |                                                 |                           |                           |
| Trospium <sup>QL</sup>                                                                 | Trospium Chloride Tab (all strengths)           | Determined pursuant to PA | Determined pursuant to PA |
| Vesicare LS <sup>AR</sup>                                                              |                                                 |                           |                           |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs with different active ingredients
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Vesicare LS: a PA is required for patients younger than 2 years old AND 5 years and older

**AR** - Myrbetriq Granules: a PA is required for patients younger than 3 years old AND 5 years

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=68&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=77){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=25){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
